Tag: Pharmaceutical

JOHNSON & JOHNSON
United States

Johnson & Johnson Strengthens Neuroscience Leadership with Acquisition of Intra-Cellular Therapies, Inc.

Acquisition includes CAPLYTA® (lumateperone), the first and only U.S. FDA-approved treatment for bipolar I and II depression as an adjunctive and monotherapy; also approved for the treatment of schizophrenia in adults sNDA submitted to U.S. FDA for CAPLYTA® as adjunctive treatment for major depressive disorder; if approved, CAPLYTA® has potential to become a standard of care for most common depressive disorders CAPLYTA® adds to Johnson & Johnson’s robust lineup of … Continue reading Johnson & Johnson Strengthens Neuroscience Leadership with Acquisition of Intra-Cellular Therapies, Inc.

Impact Newswire
Marinus
United States

Immedica to Acquire Biopharmaceutical Company Marinus Pharmaceuticals, Inc.

Press Release – STOCKHOLM & RADNOR, Pa. – Immedica Pharma AB (Immedica), a leading global rare disease company, and Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company committed to improving the lives of patients with seizure disorders, today announced that they have entered into an agreement and plan of merger under which Immedica has agreed to acquire Marinus, by means of a tender offer and subsequent merger. … Continue reading Immedica to Acquire Biopharmaceutical Company Marinus Pharmaceuticals, Inc.

Impact Newswire
abbvie
United States

AbbVie Completes Acquisition of Aliada Therapeutics

NORTH CHICAGO, Ill., Dec. 11, 2024 /PRNewswire/ — AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of Aliada Therapeutics. With the completion of the acquisition, Aliada is now a part of AbbVie. Aliada’s lead investigational asset is ALIA-1758, an anti-pyroglutamate amyloid beta (3pE-Aβ) antibody, which is in development for the treatment of patients with Alzheimer’s disease and is currently in a Phase 1 clinical … Continue reading AbbVie Completes Acquisition of Aliada Therapeutics

Impact Newswire
Koneksa
United States

Koneksa Appoints Eric Luthi as Chief Business Officer

Press Release – November 11, 2024 – NEW YORK – Koneksa, a healthcare technology company pioneering evidence-based digital biomarkers, announced today the appointment of Eric Luthi as Chief Business Officer. In this newly created role, Mr. Luthi brings over 25 years of experience in life sciences and will lead corporate and business development initiatives at Koneksa. “I’m honored to join Koneksa as we continue to … Continue reading Koneksa Appoints Eric Luthi as Chief Business Officer

Impact Newswire
Kashiv BioSciences
United States

Kashiv BioSciences Appoints Dr. Sandeep Nilkanth Athalye as Global CEO

Press Release – November 01, 2024 – PISCATAWAY, N.J. – Kashiv BioSciences, LLC, a global vertically integrated biopharmaceutical company, is pleased to announce the appointment of Dr. Sandeep NilkanthAthalye as Global Chief Executive Officer. Dr. Athalye, a seasoned leader with over two decades of experience in strategic and operational roles within the global pharmaceutical industry, will oversee company operations and drive strategic growth across key markets, … Continue reading Kashiv BioSciences Appoints Dr. Sandeep Nilkanth Athalye as Global CEO

Impact Newswire
Alpha Cognition
Global

Alpha Cognition Announces Appointment of VP Finance and Accounting

October 21, 2024 – VANCOUVER, British Columbia – Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF)(“Alpha Cognition” or the “Company”), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, announces that Henry Du has joined Alpha Cognition as the VP of Finance and Accounting and interim Chief Financial Officer (CFO). “I am excited to join Alpha Cognition at such a critical juncture” Post … Continue reading Alpha Cognition Announces Appointment of VP Finance and Accounting

Impact Newswire
sanofi
Europe

Sanofi and CD&R partner to fuel Opella’s ambitions in consumer healthcare

October 21, 2024 – Press Release Sanofi and CD&R partner to fuel Opella’s ambitions in consumer healthcare Paris, October 21, 2024. Sanofi and CD&R announce today a plan to join forces to fuel Opella’s ambitions as a French-headquartered, global consumer healthcare champion. Sanofi and CD&R have entered exclusive negotiations for the potential sale and purchase of a 50% controlling stake in Opella. This new step in … Continue reading Sanofi and CD&R partner to fuel Opella’s ambitions in consumer healthcare

Impact Newswire
Luxa Biotechnology
United States

Luxa Biotechnology LLC Appoints Keith E. Dionne, Ph.D., as Chief Executive Officer

FORT LEE, N.J. – Luxa Biotechnology LLC (Luxa), a clinical -stage biotechnology company developing a novel adult retinal pigment epithelial stem cell (RPESC) therapy for dry age-related macular degeneration (AMD), today announced the appointment of Keith Dionne, Ph.D. as Chief Executive Officer. “I am honored to join Luxa at such an exciting time” Post this An early pioneer in the cell therapy field and a … Continue reading Luxa Biotechnology LLC Appoints Keith E. Dionne, Ph.D., as Chief Executive Officer

Impact Newswire
Resilience
United States

Resilience Appoints Dr. Susan Billings, Chief Commercial Officer

SAN DIEGO – National Resilience, Inc. (Resilience), a technology-focused biomanufacturing company dedicated to broadening access to complex medicines, today announced that Dr. Susan Billings will join the company as Chief Commercial Officer. In this pivotal role, Susan will lead Resilience’s commercial organization, focusing on brand building, revenue growth and market expansion to deliver exceptional customer-centric solutions across Resilience’s diverse biomanufacturing portfolio. “We are thrilled to welcome Susan … Continue reading Resilience Appoints Dr. Susan Billings, Chief Commercial Officer

Impact Newswire